Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffoldCohen, F., Alicke, B., Elliott, L.O., Flygare, J.A., Goncharov, T., Keteltas, S.F., Franklin, M.C., Frankovitz, S., Stephan, J.P., Tsui, V., Vucic, D., Wong, H., Fairbrother, W.J.
(2009) J Med Chem 52: 1723-1730
- PubMed: 19228017
- DOI: https://doi.org/10.1021/jm801450c
- Primary Citation of Related Structures:
3F7G, 3F7H, 3F7I
- PubMed Abstract:
- Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.
Zobel, K., Wang, L., Varfolomeev, E., Franklin, M.C., Elliott, L.O., Wallweber, H.J., Okawa, D.C., Flygare, J.A., Vucic, D., Fairbrother, W.J., Deshayes, K.
(2006) ACS Chem Biol 1: 525
- Engineering ML-IAP to produce an extraordinarily potent caspase-9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP.
Vucic, D., Franklin, M.C., Wallweber, H.J., Das, K., Eckelman, B.P., Shin, H., Elliott, L.O., Deshayes, K., Salvesen, G.S., Fairbrother, W.J.
(2005) Biochem J 385: 11
- Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP)
Franklin, M.C., Kadkhodayan, S., Ackerly, H., Alexandru, D., Distefano, M.D., Elliott, L.O., Flygare, J.A., Vucic, D., Deshayes, K., Fairbrother, W.J.
(2003) Biochemistry 42: 8223
A series of IAP antagonists based on an azabicyclooctane scaffold was designed and synthesized. The most potent of these compounds, 14b, binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domain of c-IAP1 with K(i) values of 140, 38, and 33 nM, respectively ...
A series of IAP antagonists based on an azabicyclooctane scaffold was designed and synthesized. The most potent of these compounds, 14b, binds to the XIAP BIR3 domain, the BIR domain of ML-IAP, and the BIR3 domain of c-IAP1 with K(i) values of 140, 38, and 33 nM, respectively. These compounds promote degradation of c-IAP1, activate caspases, and lead to decreased viability of breast cancer cells without affecting normal mammary epithelial cells. Finally, compound 14b inhibits tumor growth when dosed orally in a breast cancer xenograft model.
Departments of Discovery Chemistry, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, USA. email@example.com